Cetuxiamb, a monoclonal antibody against @entity470 ( @entity470 ), has been used in combination with chemotherapy for @entity1 with metastatic @entity14 (mCRC). However, the efficacy of combined therapies of cetuximab and different chemotherapy regimens remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and @entity137 of adding cetuximab to @entity901 -based or @entity2600 -based chemotherapeutic regimens for the treatment of @entity1 with mCRC with wild-type/mutated @entity984 @entity5 . Randomized controlled trials (RCTs), published in Pubmed and Embase were systematically reviewed to assess the survival benefits and @entity137 profile mCRC @entity1 treated with cetuximab plus chemotherapy. Outcomes included @entity1349 ( @entity1349 ), progression-free survival (PFS), overall response rate (ORR), and @entity137 . Results were expressed as the hazard ratio (HR) with 95  % confidence intervals (CI). Pooled estimates were generated by using a fixed-effects model or a randomized-effects model, depending on the heterogeneity among studies. A total of 12 trials involving 6,297 @entity1 met the inclusion criteria and were included in this meta-analysis. All @entity1 were administered @entity901 -based or @entity2600 -based chemotherapy with or without cetuximab. Pooled results showed that the addition of cetuximab did not significantly improve the @entity1349 (HR   =   0.99, 95  % CI   =   0.89-1.09; Z   =   0.28, P   =   0.78) or PFS (HR   =   0.94, 95  % CI   =   0.81-1.10; Z   =   0.76, P   =   0.49), but did improve ORR (RR   =   1.34, 95  % CI   =   1.08-1.65; Z   =   2.72, P   =   0.00), when compared with chemotherapy alone. Subgroup analysis showed the highest PFS benefit in @entity1 with wild-type @entity984 @entity5 (HR   =   0.80, 95  % CI   =   0.65-0.99; Z   =   2.1, P   =   0.04) or wild-type @entity984 / @entity817 @entity5 (HR   =   0.64, 95  % CI   =   0.52-0.79; Z   =   4.15, P   =   0.00). When combined with cetuximab, @entity2600 -based chemotherapy was significantly associated with prolonged PFS (HR   =   0.79, 95  % CI   =   0.66-0.96; Z   =   2.36, P   =   0.02) for all @entity1 with differing gene-status. The incidence of grade 3/4 adverse events, including @entity137 , @entity294 , @entity101 , @entity448 , and @entity33 / @entity3136 , was slightly higher in the combined therapy group than in the chemotherapy-only group. Based on the current evidence, the addition of cetuximab to chemotherapy significantly improves the PFS in @entity1 with wild-type @entity984 or wild-type @entity984 / @entity817 @entity5 as well as the ORR in all @entity1 . In addition, @entity2600 -based combination therapy showed a beneficial effect on the PFS in all @entity1 . These findings confirm the use of cetuximab in combination with chemotherapy for the treatment of @entity1 with mCRC with wild-type @entity984 @entity5 . Further multi-center RCTs are needed to indentify these findings.

Efficacy and @entity137 of adding cetuximab to chemotherapy in the treatment of metastatic XXXX : a meta-analysis from 12 randomized controlled trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'skin toxicity', 'toxicities'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
